eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

without publication fees

Open access

without publication fees
1/2021
vol. 37
 
Share:
Send email
Share:
Review paper

Pharmacotherapy of pandemic and post-pandemic stress-related mental disorders

Janusz Heitzman
1

  1. Department of Forensic Psychiatry, Institute of Psychiatry and Neurology
Farmakoterapia w Psychiatrii i Neurologii 2021, 37 (1), 9–32
Online publish date: 2021/11/17
Article file
- 01R_IPiN_FARM_2021-1D.pdf  [0.27 MB]
Get citation
 
 
1. Amos T, Stein DJ, Ipser JC. Pharmacological interventions for preventing post-traumatic stress disorder (PTSD Review). The Cochrane Collaboration, The Cochrane Library 2014, Issue 7.
2. Davidson JRT, van der Kolk BA. The Psychopharmacological treatment of Posttraumatic Stress Disorder. W: van der Kolk BA, Mc Farlane AC, Weisaeth L (ed.). Traumatic Stress, The Effects of Overwhelming Experience on Mind Body and Society. New York, Guilford, 1996, s. 511-524.
3. Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001; 25: 836-844.
4. DSM-5, Diagnostic and statistical manual of mental disorders. 5th ed., Arlington, VA: American Psychiatric Association Publishing; 2013.
5. Friedman MJ. Pharmacologic Management of Posttraumatic Stress Disorder. Primary Psychiatry 2003; 10, 8: 66-73.
6. Gaebel W, Großimlinghaus I, Mucic D, Maercker A, Zielasek J, Kerst A. EPA guidance on eMental health interventions in the treatment of posttraumatic stress disorder (PTSD). European Psychiatry 2017, 41: 140-152.
7. Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996, 57 (9): 390-394.
8. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. bioRixiv 2020; DOI: http:// doi.org/10.1101/2020.02.07.937862.
9. Green B. Zespół stresu pourazowego, nowe kierunki farmakoterapii. Med. Prakt. Psychiatria 2015; 4: 9-22.
10. Heitzman J. Wpływ pandemii COVID-19 na zdrowie psychiczne. Psychiatr. Pol. 2020; 54(2): 187-198. DOI: https:// doi.org/10.12740/PP/120373.
11. Heitzman J. Ostre zaburzenia stresowe – możliwości psychoterapeutyczne. W: J. Meder (red.). Zachowania agresywne, przeciwdziałanie, leczenie. Biblioteka Psychiatrii Polskiej, Kraków 2007, 77-92.
12. Herbert J, Goodyer IM, Grossman AB, Hastings MH, de Kloet ER, Lightman SL, Lupien SJ, Roozendaal B, Seckl JR. Do corticosteroids damage the brain? J Neuroendocrinol. 2006;18: 393-411.
13. Hoge LA, Worthington JJ, Nagurney JT et al. Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. CNS Neurosci. Therapeut. 2012; 18: 21-27.
14. ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization 1992.
15. Ipser J, Seedat S, Stein DJ. Pharmacotherapy for post-traumatic stress disorder – a systematic review and meta-analysis. S Afr Med J 2006; 96: 1088-96.
16. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post- -traumatic stress disorder (PTSD). International Journal of Neuropsychopharmacology 2011; 15(6): 825-40. DOI:10.1017/ S1461145711001209.
17. Joca SR, Ferreira FR, Guimaraes FS. Modulation of stress consequences by hippocampal monoaminergic, glutamatergic nd nitrergic neurotransmitter systems. Stress 2007; 10: 227-249.
18. Katz C, Stein M, Richardson D i wsp. A review of interventions for treatment-resistant posttraumatic stress disorder. W: Selek DS (ed.). Different views of anxety disorders, Rijeka, InTech Publishing 2011.
19. van der Kolk BA. The drug treatment of post-traumatic stress disorder. Journal of Affective Disorders 1987; 13: 203-213.
20. van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz B, Fisler R, Saxe G. Fluoxetine in posttraumatic stress disorder. Journal of Clinical Psychiatry 1994; 55(12): 517-522.
21. Krystal JH. Animal models for post traumatic stress disorder. W: Giller EL (ed.), Biological assessment and treatment of post-traumatic stress disorder. Washington DC: American Psychiatric Press; 1990, s. 3-26.
22. Landowski J. Farmakoterapia stanów lękowych. W: Bijak M, Lasoń W (red.). Neuropsychofarmakologia – dziś i jutro, Instytut Farmakologii PAN, Kraków 2000, 167-190.
23. Lo SC, Ravaldi C, Cabras PL, Faravelli C, Ricca V. Stress, hypothalamic-pituitary-adrenal axis and eating disorders. Neuropsychobiology 2008; 57: 95-115.
24. Meewisse ML, Reitsma JB, de Vries GJ, Gersons BP, Olff M. Cortisol and post-traumatic stress disorder in adults: systematic review and meta-analysis. Br J Psychiatry. 2007; 191: 387-392.
25. Morganstein JC, Ursano RJ, Fullerton CS, Holloway HC. Pandemics: Health Care Emergencies. W: Ursano RJ, Fullerton SC, Weisaeth L, Raphael B (ed.). Textbook of Disaster Psychiatry, wyd 2. Cambridge: Cambridge University Press 2017, s. 270-283.
26. Moukaddam N, Shah A. Psychiatrists Beware! The Impact of COVID-19 and Pandemics on Mental Health. Psychiatric Times 2020; 37(3): 11-12.
27. Nemeroff CB, Owens MJ. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr. 2004; 9: 23-31.
28. NICE 2018. Guidelines for post-traumatic stress disorder nice guideline (NG116). Retrieved from https://www. nice. org.uk/guidance/ng116.
29. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008; 31: 464-468.
30. Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB, Cahill L, Orr SP. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002; 51: 189-192.
31. Raphael B, Wilson J, Meldrum L, McFarlane AC. Acute preventive interventions. W: van der Kolk BA, Mc Farlane AC, Weisaeth L (ed.). Traumatic Stress, The Effects of Overwhelming Experience on Mind Body and Society. New York, Guilford 1996; 463-479.
32. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003; 160: 371-373.
33. Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 2011; 470: 492-497.
34. Ravindran LN, Stein MB. Pharmacotherapy of PTSD: Premises, Principles, and Priorities, Brain Res. 2009, Oct 13; 1293: 24-39.
35. Ritchie EC. Mass violence and early intervention: Best practice Guidelines. Primary Psychiatry 2003; 10 (8): 43-48.
36. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar- -Poli P et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID- 19 pandemic. Lancet Psychiatry 2020; Published online, May 18, 2020; https:// doi.org/10.1016/S2215-0366(20) 30219-4.
37. Roozendaal B, Okuda S, Van der Zee EA, McGaugh JL. Glucocorticoid enhancement of memory requires arousal-induced noradrenergic activation in the basolateral amygdala. Proc Natl Acad Sci USA 2006;103:6741-6746.
38. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann NY Acad Sci. 2008; 1141: 105-130.
39. Southwick S M, Krystal J H, Morgan A, Johnson D, Nagy L, Nicolaou A et al. Abnormal noradrenergic function in post- -traumatic stress disorder. Archives of General Psychiatry 1993; 50: 266-274.
40. Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 2007; 20: 923-932.
41. Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008; 63: 629-632.
42. Towers S, Afzal S, Bernal G, Bliss N, Brown S. Mass Media and the Contagion of Fear: The Case of Ebola in America. PLoS ONE 2015; http://doi.org/10.1371/journal.pone. 0129179.s001.
43. VA/DoD clinical practice guideline for management of post- -traumatic stress. Washington (DC): Department of Veterans Affairs, Department of Defense; 2010. Available from: http:// www.healthquality.va.gov/ptsd/ptsd_full.pdf.
44. VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Reaction. Washington (DC): Department of Veterans Affairs, Department of Defense; 2017, Mental Health Guidelines. Available from: https://www.healthquality.va.gov/guidelines/mh/ ptsd/index.asp.
45. Vargas MA, Bissette G, Owens MJ, Ehlers CL, Nemeroff CB. Effect of chronic ethanol and benzodiazepine treatment and withdrawal on corticotropin-releasing factor neural systems. An. N. Y. Acad. Sciences 1992, 654: 145-152.
46. Zelena D, Mergl Z, Makara GB. Glutamate agonists activate the hypothalamic-pituitary-adrenal axis through hypothalamic paraventricular nucleus but not through vasopressinerg neurons. Brain Res 2005; 1031: 185-193.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.